AstraZeneca is planning to invest $360 million to establish an active pharmaceutical ingredient (API) manufacturing facility for small molecules near Dublin, Ireland.

The new plant will allow for late-stage development and early commercial supply for AstraZeneca’s pipeline. The manufacturing facility will use advanced process technology and digital capabilities to manufacture a range of medicines, including new modalities such as antibody drug conjugates and oligonucleotides.

The $360-million planned investment at the Alexion Campus in College Park, Dublin, is expected to create about 100 jobs. The project was developed with the support and collaboration of Ireland’s investment agency, IDA Ireland.

Source: AstraZeneca